Drug Trial Radar · NCT06764303
A Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients
Last checked: Nov 19, 2026Latest source record: Sep 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Jan 23, 2025
Primary completion
Jul 8, 2025
Study completion Jul 8, 2027
Sponsor
- Lead sponsor
- Nanjing Chia-tai Tianqing PharmaceuticalIndustry
- Sponsor type
- Industry
- First posted
- Jan 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
NTQ5082 capsule is a small molecule CFB factor inhibitor. This study is a multicenter, randomized, open label phase II clinical trial aimed at evaluating the efficacy, safety, and PK/PD characteristics of NTQ5082 capsules in the treatment of patients with paroxysmal nocturnal hemoglobinuria.
Conditions
- Paroxysmal Nocturnal Hemoglobinuria
Interventions
NTQ5082 100mg qdDrug
NTQ5082 100mg qd
NTQ5082 200mg qdDrug
NTQ5082 200mg qd
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of subjects whose hemoglobin (Hb) levels continue to increase by ≥ 20 g/L compared to baselineTime frame: 12 Weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Hematology Hospital of the Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China
The First Affiliated Hospital, College of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.